Linda E Kelemen1, Graham W Warren2, Jennifer M Koziak3, Martin Köbel4, Helen Steed5. 1. Alberta Health Services-Cancer Control Alberta, 2210 2nd Street SW, Calgary, AB T2S 3C3, Canada. Electronic address: kelemen@musc.edu. 2. Department of Radiation Oncology, Medical University of South Carolina, 169 Ashley Avenue, Charleston, SC 29425, USA; Department of Cell and Molecular Pharmacology, Medical University of South Carolina, 169 Ashley Avenue, Charleston, SC 29425, USA; Hollings Cancer Center, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, USA. Electronic address: warrengw@musc.edu. 3. Alberta Health Services-Cancer Control Alberta, 2210 2nd Street SW, Calgary, AB T2S 3C3, Canada. Electronic address: jen.koziak@gmail.com. 4. Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Centre, 1403 29 Street NW, Calgary, AB, T2N 2T9, Canada. Electronic address: martin.koebel@cls.ab.ca. 5. Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, S5-131 Lois Hole Hospital, Royal Alexandra Hospital, 10240 Kingsway Ave, Edmonton, AB T5H 3V9, Canada. Electronic address: helen.steed@albertahealthservices.ca.
Abstract
OBJECTIVE: Tobacco smoking by cancer patients is associated with increased mortality. Less is known of the impact of smoking on recurrence risk and interaction with chemotherapy treatment. We examined these associations in ovarian cancer. METHODS: Patients were identified from the Alberta Cancer Registry between 1978 and 2010 and were oversampled for less-common histologic ovarian tumor types. Medical records were abstracted for 678 eligible patients on lifestyle, medical and cancer treatment, and review of pathology slides was performed for 605 patients. We estimated hazard ratios (HR) and 95% confidence intervals (CI) using Cox proportional hazard models adjusted for age at diagnosis, race, stage and residual disease. RESULTS: Among patients receiving adjuvant chemotherapy (N=432), current smoking was significantly associated with shorter duration of overall (OS; HR, 8.56; 95% CI, 1.50-48.7) and progression-free (PFS; HR, 5.74; 95% CI, 1.05-31.4) survival from mucinous ovarian cancer only. There was no significant association between neoadjuvant chemotherapy and survival. However, among patients receiving neoadjuvant chemotherapy (N=44), current smokers had shorter PFS (HR, 4.32; 95% CI, 1.36-13.8; N=32 progressed/9 censored events) compared to never smokers, but the HRs were not statistically different across smoking categories (P interaction=0.87). CONCLUSIONS: Adverse associations were observed between smoking status and OS or PFS among patients with mucinous ovarian cancer receiving adjuvant chemotherapy. No significant effect was found from neoadjuvant chemotherapy on PFS overall; however, smoking may modify this association. Although needing replication, these findings suggest that patients may benefit from smoking cessation interventions prior to treatment with chemotherapy.
OBJECTIVE:Tobacco smoking by cancerpatients is associated with increased mortality. Less is known of the impact of smoking on recurrence risk and interaction with chemotherapy treatment. We examined these associations in ovarian cancer. METHODS:Patients were identified from the Alberta Cancer Registry between 1978 and 2010 and were oversampled for less-common histologic ovarian tumor types. Medical records were abstracted for 678 eligible patients on lifestyle, medical and cancer treatment, and review of pathology slides was performed for 605 patients. We estimated hazard ratios (HR) and 95% confidence intervals (CI) using Cox proportional hazard models adjusted for age at diagnosis, race, stage and residual disease. RESULTS: Among patients receiving adjuvant chemotherapy (N=432), current smoking was significantly associated with shorter duration of overall (OS; HR, 8.56; 95% CI, 1.50-48.7) and progression-free (PFS; HR, 5.74; 95% CI, 1.05-31.4) survival from mucinous ovarian cancer only. There was no significant association between neoadjuvant chemotherapy and survival. However, among patients receiving neoadjuvant chemotherapy (N=44), current smokers had shorter PFS (HR, 4.32; 95% CI, 1.36-13.8; N=32 progressed/9 censored events) compared to never smokers, but the HRs were not statistically different across smoking categories (P interaction=0.87). CONCLUSIONS: Adverse associations were observed between smoking status and OS or PFS among patients with mucinous ovarian cancer receiving adjuvant chemotherapy. No significant effect was found from neoadjuvant chemotherapy on PFS overall; however, smoking may modify this association. Although needing replication, these findings suggest that patients may benefit from smoking cessation interventions prior to treatment with chemotherapy.
Authors: Elizabeth L Kacel; Janae L Kirsch; Timothy S Sannes; Seema Patidar; Rachel Postupack; Sally Jensen; Shan Wong; Stephanie Garey; Stacy Dodd; Chantel M Ulfig; Christina S McCrae; Michael E Robinson; Jacqueline Castagno; Gregory S Schultz; Deidre B Pereira Journal: Health Psychol Date: 2019-08-01 Impact factor: 4.267
Authors: Camilla Praestegaard; Allan Jensen; Signe M Jensen; Thor S S Nielsen; Penelope M Webb; Christina M Nagle; Anna DeFazio; Estrid Høgdall; Mary Anne Rossing; Jennifer A Doherty; Kristine G Wicklund; Marc T Goodman; Francesmary Modugno; Kirsten Moysich; Roberta B Ness; Robert Edwards; Keitaro Matsuo; Satoyo Hosono; Ellen L Goode; Stacey J Winham; Brooke L Fridley; Daniel W Cramer; Kathryn L Terry; Joellen M Schildkraut; Andrew Berchuck; Elisa V Bandera; Lisa E Paddock; Leon F Massuger; Nicolas Wentzensen; Paul Pharoah; Honglin Song; Alice Whittemore; Valerie McGuire; Weiva Sieh; Joseph Rothstein; Hoda Anton-Culver; Argyrios Ziogas; Usha Menon; Simon A Gayther; Susan J Ramus; Alexandra Gentry-Maharaj; Anna H Wu; Celeste L Pearce; Malcolm Pike; Alice W Lee; Rebecca Sutphen; Jenny Chang-Claude; Harvey A Risch; Susanne K Kjaer Journal: Int J Cancer Date: 2017-01-24 Impact factor: 7.396
Authors: Naoko Sasamoto; Tianyi Wang; Mary K Townsend; A Heather Eliassen; Fred K Tabung; Edward L Giovannucci; Ursula A Matulonis; Kathryn L Terry; Shelley S Tworoger; Holly R Harris Journal: Br J Cancer Date: 2022-06-27 Impact factor: 9.075
Authors: Jennifer A Doherty; Allan Jensen; Linda E Kelemen; Celeste L Pearce; Elizabeth Poole; Joellen M Schildkraut; Kathryn L Terry; Shelley S Tworoger; Penelope M Webb; Nicolas Wentzensen Journal: J Natl Cancer Inst Date: 2017-10-01 Impact factor: 13.506
Authors: Elyse R Park; Jamie S Ostroff; Giselle K Perez; Kelly A Hyland; Nancy A Rigotti; Sarah Borderud; Susan Regan; Alona Muzikansky; Emily R Friedman; Douglas E Levy; Susan Holland; Justin Eusebio; Lisa Peterson; Julia Rabin; Jacob Miller-Sobel; Irina Gonzalez; Laura Malloy; Maureen O'Brien; Suhana de León-Sanchez; C Will Whitlock Journal: Contemp Clin Trials Date: 2016-07-19 Impact factor: 2.226
Authors: Renée T Fortner; Elizabeth M Poole; Nicolas A Wentzensen; Britton Trabert; Emily White; Alan A Arslan; Alpa V Patel; V Wendy Setiawan; Kala Visvanathan; Elisabete Weiderpass; Hans-Olov Adami; Amanda Black; Leslie Bernstein; Louise A Brinton; Julie Buring; Tess V Clendenen; Agnès Fournier; Gary Fraser; Susan M Gapstur; Mia M Gaudet; Graham G Giles; Inger T Gram; Patricia Hartge; Judith Hoffman-Bolton; Annika Idahl; Rudolf Kaaks; Victoria A Kirsh; Synnove Knutsen; Woon-Puay Koh; James V Lacey; I-Min Lee; Eva Lundin; Melissa A Merritt; Roger L Milne; N Charlotte Onland-Moret; Ulrike Peters; Jenny N Poynter; Sabina Rinaldi; Kim Robien; Thomas Rohan; Maria-José Sánchez; Catherine Schairer; Leo J Schouten; Anne Tjonneland; Mary K Townsend; Ruth C Travis; Antonia Trichopoulou; Piet A van den Brandt; Paolo Vineis; Lynne Wilkens; Alicja Wolk; Hannah P Yang; Anne Zeleniuch-Jacquotte; Shelley S Tworoger Journal: Int J Cancer Date: 2019-01-14 Impact factor: 7.396
Authors: Tianyi Wang; Mary K Townsend; A Heather Eliassen; Kathryn L Terry; Mingyang Song; Melinda L Irwin; Shelley S Tworoger Journal: Int J Cancer Date: 2021-05-21 Impact factor: 7.316
Authors: Albina N Minlikeeva; Rikki Cannioto; Allan Jensen; Susanne K Kjaer; Susan J Jordan; Brenda Diergaarde; J Brian Szender; Kunle Odunsi; Hani Almohanna; Paul Mayor; Kirsten Starbuck; Emese Zsiros; Elisa V Bandera; Daniel W Cramer; Jennifer A Doherty; Anna DeFazio; Robert Edwards; Ellen L Goode; Marc T Goodman; Estrid Høgdall; Keitary Matsuo; Mika Mizuno; Christina M Nagle; Roberta B Ness; Lisa E Paddock; Celeste L Pearce; Harvey A Risch; Mary Anne Rossing; Kathryn L Terry; Anna H Wu; Francesmary Modugno; Penelope M Webb; Kirsten B Moysich Journal: Cancer Causes Control Date: 2019-03-23 Impact factor: 2.532
Authors: Brian P Jenssen; Robert Schnoll; Rinad Beidas; Justin Bekelman; Anna-Marika Bauer; Callie Scott; Sarah Evers-Casey; Jody Nicoloso; Peter Gabriel; David A Asch; Alison Buttenheim; Jessica Chen; Julissa Melo; Lawrence N Shulman; Alicia B W Clifton; Adina Lieberman; Tasnim Salam; Kelly Zentgraf; Katharine A Rendle; Krisda Chaiyachati; Rachel Shelton; E Paul Wileyto; Sue Ware; Frank Leone Journal: Implement Sci Date: 2021-07-15 Impact factor: 7.327